Five of Wuxi Biologics' manufacturing facilities in China passed the Pre-License Inspection by the US Food and Drug Administration, the Chinese biotech giant said today. The #FDA’s inspection covered the quality management system and production processes of two drug substance and three drug product facilities in Wuxi, China.